Table 1.

Predicted survival with PAH-specific therapy using weighted mean changes from baseline in RCTs.

	Predicted survival*
Treatment	Year 1	Year 2	Year 3
Placebo	0.719	0.600	0.504
Bosentan	0.778	0.677	0.593
Sitaxentan
100 mg	0.758	0.651	0.562
300 mg	0.757	0.649	0.560
Sildenafil
20 mg	0.752	0.642	0.552
40 mg	0.756	0.648	0.559
80 mg	0.771	0.668	0.583
Epoprostenol	0.784	0.686	0.603
Beraprost	0.741	0.629	0.537
Treprostinil	0.761	0.655	0.567

*Based on the NIH Registry equation.